Moderna, Inc.
MRNA
Rank in Stocks
#260
Moderna, Inc., a biotechnology firm, is dedicated to the discovery,... Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Share Price
$226.23
Last synced: 2026-10-19
Market Cap
$90.32B
Change (1 day)
3.77%
Change (1 year)
730.52%
Country
US
Trade Moderna, Inc. (MRNA)
Category
Healthcare
P/B ratio for Moderna, Inc. (MRNA)
P/B ratio as of October 2026 TTM: 13.25
According to Moderna, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 13.25. At the end of 2023 the company had a P/B ratio of 2.74.
P/B ratio history for Moderna, Inc. from 2016 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 13.25 | 807.86% |
| 2024 | 1.46 | -46.59% |
| 2023 | 2.74 | -25.90% |
| 2022 | 3.70 | -48.86% |
| 2021 | 7.24 | -53.48% |
| 2020 | 15.56 | 182.43% |
| 2019 | 5.51 | 67.86% |
| 2018 | 3.28 | -70.66% |
| 2017 | 11.18 | 689.81% |
| 2016 | 1.42 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -52.84% |
US
|
|
| 4.208 | -68.25% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -53.36% |
NL
|
|
| 3.2932 | -75.15% |
BE
|
